Siemens Healthineers Launches Accela Radiotherapy Solution with NeoArc DMAT Technology
Siemens Healthineers has announced the launch of Accela, the first radiotherapy solution engineered around NeoArc, combining speed and precision for a broad range of cases while improving the scalability of complex treatments and reducing the time patients spend in radiotherapy treatment. NeoArc dynamic modulated arc therapy (DMAT) is a technique that combines speed and precision, making single breath-hold stereotactic treatment possible and enabling multi-site stereotactic body radiation therapy (SBRT) treatment in as little as 60 seconds.
Accela brings enhanced linac functionality, including a large HyperSight cone-beam CT imaging panel, a newly designed multi-leaf collimator, high-speed gantry rotation at 2.5 RPM, dose rates up to 40 Gy/min, and a new eight-megavolt flattening filter-free energy setting. The planning software’s advanced AI and algorithms allow clinicians to balance optimization of plan quality and delivery speed.
For healthcare systems facing a rising cancer burden, growing treatment complexity, and staffing constraints, Accela expands radiotherapy treatment options, enables faster, more precise workflows, and improves the experience for patients and clinicians.
The development of Accela and NeoArc was informed through years of collaboration by Siemens Healthineers and an advisory group of leading cancer-research institutions: Mayo Clinic, Washington University School of Medicine Siteman Cancer Center, University Hospital Zurich, Seidman Cancer Center at University Hospitals Cleveland Medical Center, Maastro – Maastricht Radiation Oncology Institute, Mass General Brigham Cancer Center, and Memorial Sloan Kettering Cancer Center. Their clinical input, research collaboration, and product evaluation have helped guide this innovation.
Dee Khuntia, MD, Chief Medical Officer at Varian, the Siemens Healthineers cancer-care business, said Accela is the kind of leap the field does not see often. Khuntia noted that the system is faster than previous systems, built on a fundamentally modern architecture, and introduces a generational shift in treatment planning, adding that what excites him most is its potential to alter the biological response to radiotherapy, which represents a new chapter rather than incremental progress.
Arthur Kaindl, Head of Varian, said today’s announcement shows a level of innovation in radiotherapy that only Siemens Healthineers can deliver. Kaindl noted that it stands on a foundation that took decades to build, including a global imaging business, a radiation-oncology installed base, mature AI and software, and long-term clinical relationships, and expressed gratitude to the thousands of colleagues whose work and ingenuity over the past eight years have brought the company to this point.
